Bioaccelerate Holdings, Inc. Helping to Fill the Pharmaceuticals Pipeline Gap
15. Dezember 2005 10:00 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Dec. 15, 2005 (PRIMEZONE) -- As pharmaceutical companies increasingly concentrate on core competencies of sales and marketing, more alternatives to self-sufficiency from R&D are being...
Bioaccelerate Portfolio Company Enhance Biotech Receives Approval for Phase I Clinical Trials
07. Dezember 2005 11:36 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Dec. 7, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announced that its portfolio company, Enhance Biotech Inc. (Pink Sheets:EBOI), a Specialty Pharmaceutical company...
Bioaccelerate Appoints Professor Sir Charles George to Board of Directors
03. November 2005 07:39 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK and LONDON, Nov. 3, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announces that Sir Charles George has agreed to be appointed to the Board of Directors.
Professor Sir...
Bioaccelerate, Inc.: Proven, Effective Treatment for Psoriasis Now in Clinical Development in North America
01. November 2005 08:46 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Nov. 1, 2005 (PRIMEZONE) -- Few diseases cause more misery than psoriasis, a condition that occurs when a person's immune system overreacts and begins to attack the skin. Psoriasis is a...
Newport Pharmaceuticals Ltd. Announces Update on Co-Development Program For Isoprinosine
31. Oktober 2005 12:59 ET
|
Gardant Pharmaceuticals, Inc.
DUBLIN, Ireland, Oct. 31, 2005 (PRIMEZONE) -- Newport Pharmaceuticals Ltd (NPL), a privately owned company focusing on immunological disorders, commented today on its phase II clinical development...
Bioaccelerate Announces the Appointment of Ronald A. Martell to Its Board of Directors
14. Oktober 2005 13:39 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Oct. 14, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc, (OTCBB:BACL) announces that it has appointed Ronald A. Martell to its Board of Directors.
Ronald Martell currently serves as...
Bioaccelerate Announces the Appointment of George Butler, Phd to its Board of Directors
05. Oktober 2005 13:22 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Oct. 5, 2005 (PRIMEZONE) -- Bioaccelerate Holdings, Inc., (OTCBB:BACL) today announces that it has appointed Dr George Butler, to its board of directors. Dr. Butler will serve as a...
Bioaccelerate Appoints Mark Davison as Head of CNS Division
16. September 2005 10:58 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Sept. 16, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announced that it has appointed Mark Davison as the Head of its CNS division.
Mark Davison has over sixteen...
Evolve Oncology, Inc. Appoints Paul A. Hopper as Chief Executive Officer
22. August 2005 10:17 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Aug. 22, 2005 (PRIMEZONE) -- Evolve Oncology, Inc. (Pink Sheets:EVON), a clinical stage drug development company founded by Bioaccelerate Holdings, Inc. (OTCBB:BACL), announced today the...
Bioaccelerate Appoints Frank Armstrong as Chief Operating Officer
05. Januar 2005 09:31 ET
|
Gardant Pharmaceuticals, Inc.
NEW YORK, Jan. 5, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc. (OTCBB:BACL) today announced that Dr. Frank Armstrong BSc (Hons) FRCPE, FFPM has agreed to join Bioaccelerate as its Chief Operating...